🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity ◆ Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing ◆ Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich ◆ Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery ◆ Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma ◆ Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide ◆ The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany ◆ Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact ◆ Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity ◆ Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing ◆ Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich ◆ Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery ◆ Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma ◆ Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide ◆ The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany ◆ Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact ◆
Clinical Trials in Poland / NCT07763106
Starting soon Not applicable

Effectiveness and Costs of Pressure Ulcer Treatment and the Quality of Life of Patients With Pressure Ulcers Receiving Home-Based and Institutional Care

NCT07763106 · tracked via the Priya Life Science Poland tracker
Phase
Not applicable
Started
2026-09-01
Last updated
2026-08-13

Condition(s) studied

Pressure Ulcer (PU)Pressure Ulcers, Bedsores, Decubitus UlcerQuality of LifeINSTITUTIONAL CAREWound ClosureWound Care

Investigational drug(s) / intervention(s)

residential home care treatmentlong-term care treatment

residential home care treatment: residential home care treatment

long-term care treatment: long-term care treatment

Study summary

A study aimed at comparing the effectiveness of treatment, costs, and quality of life of patients with pressure ulcers in home care and institutional care.

Eighty individuals aged 60-90 years with stage II-IV pressure ulcers can participate in the study.

Participants will be assessed for factors such as health status, independence, mood, and quality of life.

The study will allow for better tailoring care to patients' needs. Other benefits of participating in the study is that the participants will receive a detailed assessment of their health, nutrition, quality of life, as well as support in managing their pressure ulcers. They will receive regular care and medical evaluations, which may positively impact their health and well-being.

Refusing to participate in this study will not affect the patients treatment in any way.

Please ask if there is anything that is unclear or if you would like additional information.

Taking part in this study is entirely voluntary.

Eligibility

Sex
ALL
Min age
60 Years
Max age
90 Years
Healthy volunteers
No
Inclusion Criteria: * Women and men aged 60 to 90 years, * stage II-IV pressure ulcers in the lumbar-sacral area of the trunk, pelvic girdle, and lower limbs, * high risk of pressure ulcers (above 15 points on the Waterlow scale), * daily functional ability below 40 points on the Barthel scale, * consent from the patient or legal guardian/caregiver to participate in the study. Exclusion Criteria: * General contraindications (acute inflammatory conditions and febrile illnesses, venous thrombosis, cachexia), * pressure ulcers requiring surgical treatment (black necrosis, inflammation of bones and soft tissues), * tunneling pressure ulcers showing signs of acute inflammation, * pressure ulcers showing signs of infection (causing fever, swelling, pain, and unpleasant odor), * pressure ulcers with a surface area of less than 0.5 cm2, * pressure ulcers occurring on the lower legs or feet in patients with acute and chronic venous insufficiency and diabetes, * multiple pressure ulcers (\>2), * malignant tumors, * decompensated diabetes, * end-stage chronic heart failure, * end-stage renal disease, * mental illness.

Primary outcome measure(s)

Trial sites (3)

FacilityCityRegionStatus
Department of Clinical Physiotherapy, Jerzy Kukuczka Academy of Physical Education in Katowice, 72A Mikolowska Street Katowice Silesian Voivodeship
LASERPOLAK, 92 Slowackiego Street, Myszkow Katowice Silesian Voivodeship
Salus Care Center, 12 Jastrzebska Street Rybnik Silesian Voivodeship

More The Jerzy Kukuczka Academy of Physical Education in Katowice trials in Poland

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07763106 on ClinicalTrials.gov ↗ ← All trials in Poland